Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

NCT06582875 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a medication called a GLP-1 receptor agonist can slow the growth of kidneys in adults with autosomal dominant polycystic kidney disease and obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 126 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2025-03 · est. completion 2029-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06582875 ↗

Description as written by the study sponsor.

The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.

Treatments tested

Tirzepatide also known as Zepbound Drug

Titrated to dose of 5 mg once weekly subcutaneous
Placebo Other

Titrated to dose of 5 mg once weekly subcutaneous

Main thing measured	Change in height-Adjusted Total kidney volume
Sponsor	University of Colorado, Denver
Conditions studied	Autosomal Dominant Polycystic Kidney, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06582875 ↗